Rationale for Estrogen With Interrupted Progestin as a New Low-Dose Hormonal Replacement Therapy

Abstract

Objective: This review outlines the basic principles of a novel interrupted progestin hormone replacement therapy (HRT) regimen in which estrogen is given continuously but the progestin is administered in a 3-days-on and 3-days-off schedule. The rationale for this regimen is to prevent receptor down-regulation and allow estrogen to increase estrogen and progestin sensitivity during the progestin-free periods.

Methods: The reasons for poor patient acceptance of HRT are reviewed. The association of HRT with breast and endometrial cancer is discussed, as are the potential benefits of HRT on the skeleton and the cardiovascular system. Basic research studies in the rat are described that provide supporting evidence for the interrupted progestin regimen. Clinically, we review a pilot study examining symptom control, bleeding rates, and safety of the interrupted progestin regimen as well as preliminary results of the usefulness of this regimen for add-back therapy in GnRH agonist-treated patients.

Results: Estrogen and progestin receptor measurements in the rat uterus demonstrate a clear up- and down-regulation in response to estrogen and interrupted progestin but not to the continuous administration of estrogen and progestin or estrogen alone. In addition, we found a significant beneficial effect of a low-dose interrupted HRT regimen on bone mineral content and density in an aged rat model of osteopenia, compared with continuous estrogen and progestin or estrogen alone. These results support the hypothesis that the interrupted progestin HRT increases tissue sensitivity to both estrogen and progestin. Clinical studies demonstrated good symptom control, low bleeding rates, endometrial protection, and excellent patient acceptance.

Conclusion: The combination of continuous estrogen with interrupted progestin appears to result in increased sensitivity to estrogen and progestin in estrogen-responsive tissues. As a result, lower does of estrogen and progestin may be used for HRT with good biological effects. Further clinical studies, preferably in prospective randomized trials, are required to demonstrate reduced bleeding and improved patient acceptance of this new regimen compared to continuous combined HRT.

Keywords

Hormonal replacement therapy interrupted progestin estrogen receptors progestin receptors breakthrough bleeding bone mineral density menopausal women

Get full access to this article

View all access options for this article.

References

1. Ravnikar VA . Compliance with hormone replacement therapy: Are women receiving the full impact of hormone replacement therapy preventative health benefits? Womens Health Issues 1992;2:75-80.

2. Casper RF . Compliance problems with hormonal replacement. J Soc Obstet Gynecol Can 1992;14:43-45.

3. Hulka BS , Kaufman DG , Fowler WC Jr , Grimson RC , Greenberg BG . Predominance of early endometrial cancers after long-term estrogen use. JAMA 1980;244:2419-2422.

4. Jick H , Watkins RN , Hunter JR , et al. Replacement estrogens and endometrial cancer. N Engl J Med 1979:300:218-222.

5. Colditz GA , Hankinson SE , Hunter DJ , et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-1593.

6. Evan G , Harrington E , Fanidi A , Land H , Amati B , Bennett M . Integrated control of cell proliferation and cell death by the c-myc oncogene. Philos Trans R Soc Lond [Biol] 1994;B345:269-275.

7. Colborn T , vom Saal FS , Soto AS . Developmental effects of endocrine-disrupting chemicals in wildlife and humans. Environ Health Perspect 1993;101:378-384.

8. Van der Burg B , De Groot RP , Isbrucker L , Krulier W , deLaat SW . Direct stimulation by estrogen of growth factor signal transduction pathways in human breast cancer cells. J Steroid Biochem Molec Biol 1992;43:111-115.

9. Bhargava V , Kell DL , van de Rijn M , Wamke RA . Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 1994;145:535-540.

10.

10. Clarke CL , Sutherland RL . Progestin regulation of cellular proliferation. Endocrine Rev 1990;11:266-301.

11.

11. de Lignieres B , Linares G , Barrat J . Effects of progesterone on epithelial cell mitotic activity in human breast. In: Progesterone in hormonal replacement therapy. Lobo RA , Naftolin F. Park Ridge, New Jersey: The Parthenon Publishing Group, 1992:47-56.

12.

12. Dupont WD , Page DL . Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991;151:67-72.

13.

13. King RJB . Progression from steroid sensitive to insensitive state in breast tumours. Cancer Surv 1992;14:131-146.

14.

14. Zhang Q-X , Borg A , Fuqua SAW . An exon 5 deletion variant of the estrogen receptor frequently coexpressed with wild-type estrogen receptor in human breast cancer. Cancer Res 1993;53:5882-5884.

15.

15. Henderson BE , Paganini-Hill A , Ross RK . Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75-78.

16.

16. Bergkvist L , Adami HO , Persson I , Bergstrom R , Krusemo UB . Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 1989;30:221-228.

17.

17. Ferenczy A , Gelfand M . The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 1989;160:126-131.

18.

18. Jick H , Watkins RS , Hunter JR , et al. Replacement estrogens and endometrial cancer. N Engl J Med 1979;300:218-218.

19.

19. Collins JA , Allen LH , Donner A . Oestrogen use and survival in endometrial cancer. Lancet 1980;ii:961-964.

20.

20. Elwood JM , Boyes DA . Clinical and pathological features and survival of endometrial cancer patients in relation to prior use of estrogens. Gynecol Oncol 1980;10:173-187.

21.

21. Gambrell RD Jr , Massey FM , Castaneda TA , Ugenas AJ , Ricci CA , Wright JM . Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet Gynecol 1980;55:732-738.

22.

22. Studd JWW , Thom MH , Patterson MEL , Wade-Evans T . The prevention and treatment of endometrial pathology in postmenopausal women receiving exogenous estrogens. In: The menopause and postmenopause. Pasetto N , Paoletti R , Armbus JL , eds. Lancaster MPT Press, 1980:127-127.

23.

23. Kreitmann-Gimbal B , Bayard F , Nixon WE , Hodgen GD . Patterns of estrogen and progesterone receptors in monkey endometrium during the normal menstrual cycle. Steroids 1980;35:471-479.

24.

24. West NB , Brenner RM . Progesterone-mediated suppression of estradiol receptors in cynomolugs macaque cervix, endometrium and oviduct during sequential estradiol-progesterone treatment. J Steroid Biochem 1985;22:29-37.

25.

25. Whitehead MI , Townsend PT , Pryce-Davies J , Ryder TA , King RJ . Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 1981;305:1599-1605.

26.

26. King RJB , Townsend PT , Siddle N , Whitebead MI , Taylor RW . Regulation of estrogen and progesterone receptor levels in epithelium and stroma from pre and postmenopausal endometria. J Steroid Biochem 1982;16:21-29.

27.

27. Gurpide E . Enzymatic modulation of hormonal action at the target tissue. J Toxicol Environ Health 1978;4:249-268.

28.

28. Prior JC . Progesterone as a bone-trophic hormone. Endocrinol Rev 1990;11:386-398.

29.

29. Mandei FP , Davidson BJ , Erlik Y , Judd HL , Meldrum DR . Effects of progestins on bone metabolism in post menopausal women. J Reprod Med 1982;27(suppl. 8):511-514.

30.

30. Christiansen C , Nilas L , Riis BJ , Rodbro P , Deftos LJ: Uncoupling of bone formation and resorption by combined oestrogen and progestagen therapy in postmenopausal osteoporosis. Lancet 1985;ii:800-801.

31.

31. Nachtigall LE , Nachtigall RH , Nachtigall RD , Beckman EM . Estrogen replacement therapy: A 10-year prospective study in relationship to osteoporosis. Obstet Gynecol 1979;53:277-281.

32.

32. Komm BS , Terpening CM , Benz DJ , et al. Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science 1988;241:81-83.

33.

33. Eriksen EF , Colvard DS , Berg NJ , et al. Evidence of estrogen receptors in normal human osteoblast-like cells. Science 1988;241:84-86.

34.

34. Karambolova KK , Snow GR , Anderson C . Effects of continuous 17β-estradiol administration on periosteal and corticoendosteal envelope activity in spayed beagles. Calcif Tissue Int 1987;40:12-15.

35.

35. Snow GR , Anderson C . The effect of 17 beta estradiol and progestagen on trabecular bone remodelling in oophorectomized dogs. Calcif Tissue Int 1986;39:198-205.

36.

36. Karambolova KK , Snow GR , Anderson C . surface activity on the periosteal and corticoendosteal envelopes following continuous progestogen supplementation in spayed beagles. Calcif Tissue Int 1986;38:239-243.

37.

37. Manolagas SC , Anderson DC . Detection of high-affinity glucocorticoid binding in rat bone. J Endocrinol 1978;76:379-380.

38.

38. Chen TL , Aronow L , Feldman DL . Glucocorticoid receptors and inhibition of bone cell growth in primary culture. Endocrinology 1977;100:619-628.

39.

39. Tikkanen MJ , Nikkila EA , Kuusi T . Sipinen S . Reduction of plasma high-density lipoprotein-2 cholesterol and increase of postheparin plasma hepatic lipase activity during progestin treatment. Clin Chim Acta 1981;115:63-71.

40.

40. Phillips A , Demarest K , Hahn DW , Wong F , McGuire JL . Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. Contraception 1990;41:399-410.

41.

41. Colditz GA , for the Nurses Health Study Research Group . Oral contraceptive use and mortality during 12 years of follow-up: The Nurses' Health Study. Ann Int Med 1994;120:821-826.

42.

42. Adams MR , Clarkson TB , Shively CA , Parks JS , Kaplan JR . Oral contraceptives, lipoproteins and atherosclerosis. Am J Obstet Gynecol 1990;163:1388-1393.

43.

43. Clarkson TB , Shively CA , Morgan TM , Koritnik DR , Adams MR , Kaplan JR . Oral contraceptives and coronary artery atherosclerois of cynomolgues monkeys. Obstet Gynecol 1990;75:217-222.

44.

44. Wagner JD , Clarkson TB , St. Clair RW , Schwenke DC , Shively CA , Admas MR . Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. J Clin Invest 1991;88:1995-2002.

45.

45. Rifici VA , Khachadurian AK . The inhibition of low-density lipoprotein oxidation by 17-β estradiol. Metabolism 1992;41:1110-1114.

46.

46. Sack MN , Rader DJ , Cannon RO III . Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994;343:269-270.

47.

47. Williams JK , Shively CA , Clarkson TB . Determinants of coronary artery reactivity in premenopausal female cynomolgus monkeys with diet-induced atherosclerosis. Circulation 1994;90:983-987.

48.

48. Williams JK , Honore Ek , Washburn SA , Clarkson TB . Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus in cynomolgus monkeys. J Am Coll Cardiol 1994;24:1757-1761.

49.

49. Poulin R , Baker D , Poirier D , Labrie F . Androgen and glucocorticiod receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. Breast Cancer Res Treat 1989;13:161-172.

50.

50. Rousseau GG , Baxter JD , Tomkins GM . Glucocorticoid receptors: Relations between steroid binding and biological effects. J Mol Biol 1972;67:99-115.

51.

51. Walker BR , Williams BC . Corticosteroids and vascular tone: Mapping the messenger maze. Clin Sci 1992;82:597-605.

52.

52. Eckert RL , Katzenellenbogen BS . Human endometrial cells in primary tissue culture: Modulation of the progesterone receptor level by natural and synthetic estrogens in vitro. J Clin Endocrinol Metab 1981;52:699-708.

53.

53. Kreitmann-Gimbal B , Bayard F , Nixon WE , Hodgen GD . Patterns of estrogen and progesterone receptors in monkey endometrium during the normal menstrual cycle. Steroids 1980;35:471-479.

54.

54. West NB , Brenner RM . Progesterone-mediated suppression of estradiol receptors in cynomolgus macaque cervix, endometrium and oviduct during sequential estradiol-progesterone treatment. J steroid Biochem 1985;22:29-37.

55.

55. Neumannova M , Kauppila A , Kivinen S , Vihko R . Short-term effects of tamoxifen, medroxyprogesterone acetate, and their combination on receptor kinetics and 17β-hydroxysteroid dehydrogenase in human endometrium. Obstet Gynecol 1985;66:695-700.

56.

56. Whitehead MI , Townsend PT , Pryce-Davies J , Ryder TA , King RJ . Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 1981;305:1599-1605.

57.

57. Leavitt WW , Okulicz WC , McCracken JA , Schramm WS , Robidoux WF Jr . Rapid recovery of nuclear estrogen receptor and oxytocin receptor in the ovine uterus following progesterone withdrawal. J Steroid Biochem 1985;22:687-691.

58.

58. Casper RF , Yen SSC . Neuroendocrine changes during menopausal flushes. In: Neuroendocrine aspects of reproduction. Norman RL , ed. New York: Academic Press, 1983:359-378.

59.

59. Bullock JL , Massey FM , Gambrell RD Jr . Use of medroxyprogesterone acetate to prevent menopausal symptoms. Obstet Gynecol 1975;46:165-168.

60.

60. Brown TJ , Scherz B , Hochberg RB , BacLusky NJ . Regulation of estrogen receptor concentrations in the rat brain: Effects of sustained androgen and estrogen exposure. Neuroendocrinology (in press).

61.

61. Brown TJ , MacLusky NJ . Progesterone modulation of estrogen receptors in microdissected region of the rat hypothalamus. Mol Cell Neurosci 1994;5:283-290.

62.

62. Lauber AH , Mobbs CV , Muramatsu M , Pfaff DW . Estrogen receptor messenger RNA expression in rat hypothalamus as a function of genetic sex and estrogen dose. Endocrinology 1991;129:3180-3186.

63.

63. Smierly RB , Young BJ . Regulation of estrogen receptor messenger ribonucleic acid in rat hypothalamus by sex steroid hormones. Mol Endocrinol 1991;5:424-432.

64.

64. McGinnis MY , Kery LC , MacLusky Nj , McEwen BS . Steroid receptor levels in intact and ovariectomized estrogen-treated rats: An examination of quantitative, temporal and endocrine factors influencing the efficacy of an estradiol stimulus. Neuroendocrinology 1981;33:158-165.

65.

65. Vanin CM , MacLusky NJ , Grynpas MD , Casper RF . The effect of three hormone replacement regimens on bone density in the aged oophorectomized rat. Fertil Steril 1995;63:643-651.

66.

66. MacLusky NJ , Larner JM , Hochberg RB . Actions of an estadiol-17-fatty acid ester in estrogen target tissues of the rat: Comparison with other C-17 metabolites and a pharmacological C-17 ester. Endocrinology 1989;124:318-324.

67.

67. Shupnik MA , Gordon MS , Chin WW . Tissue-specific regulation of rat estrogen receptor mRNAs. Mol Endocrinol 1989;3:660-665.

68.

68. Hyder SM , Nawaz Z , Chiappetta C , Yokoyama K , Stancel GM . The protooncogene c-jun contains an unusual estrogen-inducible enhancer within the coding sequence. J Biol Chem 1995;270:8506-8513.

69.

69. Kirkland JL , Murthy L , Stancel GM . Progesterone inhibits the estrogen-induced expression of c-fos messenger ribonucleic acid in the uterus. Endocrinology 1992;130:3223-3230.

70.

70. Lingham RB , Stancel GM , Loose-Mitchell DS . Estrogen regulation of epidermal growth factor receptor messenger ribonucleic acid. Mol Endocrinol 1988;2:230-235.

71.

71. Loose-Mitchell DS , Chiappetta C , Strancel GM . Estrogen regulation of c-fos messenger ribonucleic acid. Mol Endocrinol 1988;2:946-951.

72.

72. Migliaccio A , Castoria G , de Falco A , et al. In vitro phosphorylation and hormone binding activation of the synthetic wild type human estradiol receptor. J Steroid Biochem Mol Biol 1991;38:407-413.

73.

73. Migliaccio A , Pagano M , De Goeij CCJ , Di Domenico M , Castoria G , Sluyser M , Auricchio F . Phosphorylation and estradiol binding of estrogen receptor in hormone-dependent and hormone-independent GR mouse mammary tumors. Int J Cancer 1992;51:733-739.

74.

74. Murdoch FE , Gorski J . The role of ligand in estrogen receptor regulation of gene expression. Mol Cell Endocrinol 1991;78:C103-C108.

75.

75. Stancel GM , Gardner RM , Kirkland JL , et al. Interactions between estrogen and EGF in uterine growth and function. Adv Exp Med Biol 1987;230:99-118.

76.

76. Okulicz WC , Evans RW , Leavitt WW . Progestrone regulation of the occupied form of nuclear estrogen receptor. Science 1981;213:1503-1505.

77.

77. Leavitt WW , Cobb AD , Takeda A . Progesterone-modulation of estrogen action: Rapid down regulation of nuclear acceptor sites for the estrogen receptor. Adv Exp Med Biol 1987;230:49-78.

78.

78. Brenner PF . The pharmacology of progestogens. J Reprod Med 1982;27:490-497.

79.

79. Vanin C , Chacra D , Grynpas M , MacLusky N , Casper RF . Lumbar vertebral density and mechanical properties in aged ovariectomized rats treated with estrogen and norethinedrone or norgestimate. Am J Obstet Gynecol 1995;173:1491-1498.